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Increased methylglyoxal and advanced glycation end products
in kidney from spontaneously hypertensive rats.
Background. Methylglyoxal (MG), a metabolite of glucose,
causes nonenzymatic glycation of proteins to form irreversible
advanced glycation end products (AGEs). The role of MG in the
development of essential hypertension is unknown, although
MG has been extensively studied in relation to diabetes.
Methods. Blood pressure of spontaneously hypertensive rats
(SHR) and paired Wistar Kyoto (WKY) rats was measured at
5, 8, 13, and 20 weeks of age. HPLC was used to determine the
levels of plasma and kidney MG, as well as reduced or
oxidized glutathione in the kidney. MG-induced AGEs,
Ne-carboxyethyl-lysine (CEL), and Ne-carboxymethyl-lysine
(CML) in the kidney were detected by immunohistochemistry.
Glutathione peroxidase and reductase activities in the kidney
were also determined.
Results. Plasma MG levels were significantly elevated in
SHR, but not in WKY rats, at 8, 13, and 20 weeks of age in par-
allel with blood pressure increase. Kidney MG levels in SHR
were increased by 21% and 38% at 13 and 20 weeks, respec-
tively, compared to age-matched WKY rats. There were no dif-
ferences in blood pressure and MG levels in plasma and kidney
between SHR and WKY rats at 5 weeks of age. Immunohisto-
chemistry revealed more intense staining for CML and CEL in
kidneys from SHR compared to WKY rats from 8 weeks on-
ward. Most of the staining was localized to renal tubules with
some staining in the glomerular vessels.
Conclusion. MG and AGEs formation was significantly ele-
vated in kidney from SHR, which may cause local vascular and
tubular damage, contributing to the development and compli-
cations of hypertension.
Methylglyoxal (MG), a metabolite of glucose, is a
highly reactive dicarbonyl compound formed sponta-
neously during glycolysis as a result of transformation
of triose phosphates [1]. This dicarbonyl molecule can be
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also formed during various metabolic processes, includ-
ing metabolism of acetone from lipolysis and metabolism
of threonine from protein catabolism [2, 3]. MG is detoxi-
fied by the glyoxalase system that uses glutathione (GSH)
as a cofactor [1]. MG is the most reactive AGE precur-
sor [4], and can react with selective proteins to yield
irreversible advanced glycation end products (AGEs),
leading to cross-linking and denaturation of protein [5].
The irreversible reaction of MG with lysine residues
of protein forms Ne-carboxyethyl-lysine (CEL) and Ne-
carboxymethyl-lysine (CML).
MG and related AGEs, such as CEL, have been rec-
ognized as indicators of carbonyl overload in vivo [6, 7],
and their formations are correlated with age [8, 9]. The
association of MG and AGEs with hyperglycemic states,
such as diabetes mellitus, has been intensively studied.
Increased MG production, which in turn gives rise to
AGEs, has been linked to the development of nephropa-
thy in diabetes, although the exact role of this dicarbonyl
in this process remains unclear [10]. The associations
of MG and related AGEs with hypertension, however,
are still largely unsettled. It has been reported that the
systolic blood pressure was significantly increased after
Wistar Kyoto (WKY) rats were treated with MG in drink-
ing water. This increase was associated with an increase
of aldehyde conjugate levels in kidney, not in heart or
liver [11]. An enhanced AGE formation was found in
the aorta of stroke-prone spontaneously hypertensive
rats [12]. Our previous study [13] demonstrated increased
MG and AGEs in vascular smooth muscle cells (VSMCs)
from spontaneously hypertensive rats (SHR) in compar-
ison with that from WKY rats. We also showed that MG
increased nuclear factor-kappa B p65 and intracellular
adhesion molecule-1 expression in VSMCs from SHR
[13].
The aim of the present study was to investigate whether
MG and MG-induced AGEs were increased in plasma or
kidney of SHR, and whether an increased formation of
MG and related AGEs was correlated with the devel-
opment of high blood pressure in SHR. To this end, MG
levels in plasma and kidney were determined in SHR and
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WKY rats at different hypertension development stages.
The MG-induced CML and CEL in kidney were eval-
uated in both strains. Since glutathione (GSH) plays a
role in the metabolism of MG, GSH levels, oxidized glu-
tathione (GSSG) and related enzyme activities, including
glutathione peroxidase (GSH-Px) and glutathione reduc-
tase (GSH-Red), were also evaluated.
METHODS
Animals
Male SHR and WKY rats were purchased from Charles
River laboratories (St-Constant, Quebec, Canada), and
housed in a temperature-regulated animal facility, ex-
posed to a 12-hour light/dark cycle with free access to
food and water. The standard lab rat chow, Prolab RMH
3000, contains 60% starch, 22% crude proteins, 5% crude
fat, 5% crude fiber, 6% ash, and 2% added minerals
(PMI Nutrition International, St. Louis, MO, USA).
Rats were treated in accordance with guidelines of the
Canadian Council on Animal Care, and the experimental
protocols were approved by the Animal Care Commit-
tee at the University of Saskatchewan. SHR and paired
WKY rats were compared at 4 different time points rang-
ing from 5 to 20 weeks of age. Systolic blood pressure
was determined weekly using a standard tail cuff nonin-
vasive BP measurement system (Model 29-SSP; Harvard
Apparatus, St. Laurent, QC, Canada). At the end of the
study, rats were anaesthetized with sodium pentobarbi-
tal (60 mg/kg body weight) intraperitoneally. Blood was
collected from the heart, and plasma was separated by
centrifuging blood samples at 1000g for 10 minutes at
4◦C. Kidney was isolated in ice-cold phosphate-buffered
saline (PBS), cleaned and snap-frozen in liquid nitrogen
immediately and stored at −80◦C until processing.
Tissue preparation
Tissues were pulverized with a Mikro-Dismembrator
(B. Braun Biotech International, Bethlehem, PA, USA).
Samples prepared in 10 mmol/L phosphate buffer were
sonicated over ice twice for 10 seconds each, and there-
after either stored at −80◦C after centrifugation (15,000g,
10 min) for different enzyme assays, or directly processed
by the addition of 1 mol/L perchloric acid (PCA). In the
latter case, the samples were incubated on ice for 10 min-
utes and centrifuged at 15,000g for 10 minutes to remove
the PCA-precipitated material. The supernatants were
used freshly for MG measurement.
MG measurement
Quantitation of MG was done by the widely accepted
o-phenylenediamine (o-PD)-based assay as described by
Chaplen et al [14], with some modifications. Briefly, the
supernatant of kidney homogenate or plasma was incu-
bated with 100 mmol/L o-PD (derivatizing agent) for
3 hours at room temperature. The quinoxaline deriva-
tive of MG (2-methylquinoxaline) and the quinoxaline
internal standard (5-methylquinoxaline) were measured
using a Hitachi D-7000 high-performance liquid chro-
matography (HPLC) system (Hitachi Ltd., Mississauga,
Ontario, Canada). The column was a Nova-Pak C18 col-
umn (3.9 × 15 mm, and 4 lm particle diameter; Waters,
MA, USA). The mobile phase was composed of 80%
(vol) of 10 mmol/L NaH2PO4 (pH 4.5) and 20% (vol)
of HPLC grade acetonitrile. Duplicate injections of each
sample were made. Samples were calibrated by compar-
ison with a 2-MQ standard.
Measurement of reduced and oxidized glutathione levels
The reduced GSH and oxidized GSSG levels in kidney
were determined by derivation with 5, 5′-dithio-bis (2-
nitrobenzoic acid) and reverse-phase HPLC using ultra-
violet detection, as described in our previous study [15].
Measurement of enzyme activities
The activities of GSH-Px and GSH-Red were mea-
sured according to methods described previously [16].
The measurement of GSH-Px was coupled to the reduc-
tion of GSSG formed in the peroxidase reaction. The
activity of GSH-Red was determined by monitoring the
decrease in absorbance at 340 nm based on the oxida-
tion of NADPH, which is coupled to the reduction of one
GSSG back to GSH. The enzyme activity for both GSH-
Px and GSH-Red was expressed as nmol NADPH ox-
idized/min/mg protein. Protein concentrations were de-
termined by bicinchoninic acid procedure using bovine
serum albumin (BSA) standards.
Immunohistochemistry
Immunostaining was performed using the method
described in our previous study [17]. In brief,
paraformaldehyde-fixed and OCT-embedded renal tis-
sues derived from WKY rats and SHR at different ages
were prepared. Sections of 7 to 10 lm thickness were
cut on a cryostat and picked up on poly-l-lysine coated
slides. Sections were permeabilized with 0.1% triton X-
100 in PBS for 5 minutes after 3 washes in 0.1 mol/L PBS.
Nonspecific antibody binding was blocked by incubation
for 30 minutes with normal goat serum diluted 1:30. Sec-
tions were then incubated overnight at room temperature
in a humid atmosphere in the presence of either mono-
clonal anti-CML antibody or anti-CEL antibody (Novo
Nordisk, A/S, Denmark) diluted 1:100 in PBS containing
0.1% BSA. Control sections were exposed to the dilut-
ing solution without the primary antibody added. After
the reaction with the primary antibody, the slides were
washed 3 times with PBS and incubated with antimouse
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Table 1. Basal parameters of SHR and WKY rats at different ages
Age weeks Rats BP mm Hg BW g KW g KW/BW mg/g
5 WKY 123 ± 1 107 ± 3 1.33 ± 0.08 12.43 ± 0.30
SHR 131 ± 2 98 ± 2 1.27 ± 0.01 12.96 ± 0.17
8 WKY 121 ± 1 197 ± 6 1.91 ± 0.09 9.64 ± 0.40
SHR 190 ± 3b 180 ± 4a 1.81 ± 0.01 10.1 ± 0.08
13 WKY 120 ± 1 339 ± 5 2.45 ± 0.05 7.23 ± 0.08
SHR 203 ± 1b 281 ± 7b 2.36 ± 0.02 8.4 ± 0.30
20 WKY 119 ± 1 353 ± 11 2.22 ± 0.03 6.3 ± 0.10
SHR 202 ± 1b 308 ± 4a 2.52 ± 0.08 8.15 ± 0.20
Abbreviations are: BP, systolic blood pressure; BW, body weight; KW, kidney
weight.
aP < 0.05, SHR vs. WKY of the same age group.
bP < 0.001, SHR vs. WKY of the same age group.
IgG-FITC (Sigma, St. Louis, MO, USA) diluted 1:200
for 1 hour at room temperature, followed by another
3 washes. Thereafter, the slides were mounted in PBS-
glycerin (7:3 v/v), coverslipped, and examined under a
fluorescence microscope with the appropriate filters. The
sections were independently scored by two observers in
a blinded fashion. Staining intensities of the renal tissue
were graded semiquantitatively as follows: (−) negative
staining; (−/+) occasional; (+) weak; (++) moderate;
(+++) intense staining.
Data analysis
Data are expressed as mean ± SEM and analyzed using
Student t test in conjunction with the Newman-Keuls test
where applicable. Significant difference between treat-
ments was defined at a level of P < 0.05.
RESULTS
Basal parameters of SHR
As shown in Table 1, the systolic blood pressure was
significantly higher in SHR at 8 weeks and onward com-
pared to age-matched WKY rats. During the observation
period, blood pressure increased significantly above the
initial value recorded at 5 weeks in SHR, but remained
unchanged in WKY rats. In young rats at 5 weeks of age
there was no difference in the blood pressure and body
weights between SHR and WKY rats. The body weight
of SHR was significantly lower than age-matched WKY
rats from 8 weeks onward. No significant difference was
found in kidney weight and the ratio of kidney weight
to body weight in both groups of rats at different ages.
The plasma glucose levels (mean ± SEM) of 7- and 12-
week-old SHR were 4.1 ± 0.1 mmol/L (N = 5) and 5.2 ±
0.2 mmol/L (N = 10), respectively, which were compara-
ble to those in age-matched WKY rats, 4.2 ± 0.1 mmol/L
(N = 5) at 7 weeks and 5.1 ± 0.1 mmol/L (N = 6) at
12 weeks.
Increased MG levels in plasma and kidney of SHR
As shown in Figure 1A, plasma MG level was age de-
pendently and progressively increased in SHR compared



















































Fig. 1. MG levels in kidney and plasma from WKY rats and SHR at
different ages. MG levels were measured in plasma (A), and kidney (B)
from SHR and age-matched WKY rats at 5 weeks (N = 3), 8 weeks
(N = 4), 13 weeks (N = 5), and 20 weeks (N = 4) of age. MG levels in
SHR are presented as the percentage of that in age-matched WKY. ∗P
< 0.05, SHR vs. WKY of the same age group.
to WKY rats. The plasma levels (nmol/mL) of WKY
rats/SHR at 5, 8, 13, and 20 weeks were 11.2 ± 0.44/11.3 ±
0.65 (N = 3), 9.1 ± 0.81/13.8 ± 0.72 (N = 4), 18.5 ±
2.71/30.3 ± 2.05 (N = 5), and 14.2 ± 3.48/33.6 ± 2.16
(N = 4), respectively.
In young WKY rats and SHR (5 and 8 weeks old),
there was no significant difference in kidney MG levels.
However, from 13 weeks onward the renal MG level was
significantly higher in SHR than in age-matched WKY
rats (Fig. 1B). The renal MG levels (nmol/mg protein) in
WKY rats/SHR were 0.67 ± 0.15/0.67 ± 0.12 (N = 3)
at 5 weeks, 0.79 ± 0.20/0.82 ± 0.10 (N = 4) at 8 weeks,
0.71 ± 0.06/0.91 ± 0.09 (N = 5) at 13 weeks, and 0.22 ±
0.04/0.30 ± 0.06 (N = 4) at 20 weeks, respectively.
Increased MG-induced CEL and CML in kidney of SHR
With immunohistochemical staining method, we fur-
ther investigated whether MG-induced AGEs were






Fig. 2. Immunohistochemical detection of CEL in kidney from WKY
rats and SHR at different ages. Kidney sections from SHR (right
panel) show more extensive staining than age-matched WKY rats (left
panel). Big arrows indicate the representative immunoreactivity in re-
nal tubules, and small arrows show staining in the glomerulus.
Table 2. CEL and CML staining in kidney from SHR and WKY rats
at different ages (N = 3 for each group)
Rats 5 weeks 8 weeks 13 weeks 20 weeks
CEL WKY − ++ + +
SHR −/+ +++ +++ ++
CML WKY − + −/+ −/+
SHR − ++ ++ +
Staining: (−) negative; (−/+) occasional; (+) weak; (++) moderate; (+++)
intense.
increased in kidney from SHR. Figure 2 shows more in-
tense or positive staining for CEL in kidney from SHR
compared to WKY rats at 8, 13, and 20 weeks of age
(N = 3 for each age group), respectively (Table 2). Posi-
tive CEL staining in kidney of SHR was observed occa-
sionally, even at the age of 5 weeks (Table 2). Most of the
positive staining was localized to renal tubules in both
strains. There was some staining observed in glomeru-
lar vessels, too. Staining for CML was also more marked






Fig. 3. Immunohistochemical detection of CML in kidney from WKY
rats and SHR at different ages. Kidney sections from SHR (right panel)
show more staining than age-matched WKY rats (left panel). Big arrows
indicate representative immunoreactivity in renal tubules, and small
arrows show staining in the glomerulus.
and 20 weeks of age (N = 3 for each group) (Fig. 3 and
Table 2). The control sections revealed no staining.
GSH and related enzyme activities in the kidney of SHR
As shown in Figure 4A, GSH level in kidney was
significantly decreased by 16.5% in SHR at the age
of 20 weeks (50.7 ± 4.3 nmol/mg protein) in compar-
ison with that from age-matched WKY rats (60.7 ±
3.0 nmol/mg protein). The GSH levels (nmol/mg pro-
tein) in WKY rats/SHR at 5, 8, and 13 weeks of age were
95.9 ± 9.9/94.6 ± 6.1, 82.5 ± 6.2/76.6 ± 2.6, and 67.6 ±
11.0/62.0 ± 11.0, respectively. The ratio of GSH/GSSG
was also significantly decreased in 20- week-old SHR
compared with that in age-matched WKY rats (Fig. 4B).
There was no significant difference in renal GSH levels
and GSH/GSSG ratio between SHR and WKY rats at
the relatively younger age (Fig. 4).
The renal GSH-Px activity was significantly decreased
by 14% in SHR at the age of 20 weeks (1.62 ± 0.1 nmol/mg













































Fig. 4. GSH levels and oxidative stress in kidney from WKY rats and
SHR at different ages. Renal levels of GSH (A). N = 4 for 5 and 20
weeks, and N = 7 for 8 and 13 weeks. GSH levels in SHR are presented
as the percentage of that in age-matched WKY rats. Oxidative stress in
kidney (B). N = 3 in each group. ∗P < 0.05, SHR vs. WKY of the same
age group.
protein) compared with age-matched WKY rats (1.87 ±
0.18 nmol/mg protein) (N = 3 for each group, P < 0.05).
There was no significant change in renal GSH-Px activi-
ties between SHR and WKY rats at the age of 5, 8, and
13 weeks (N = 3 for each group, P > 0.05). No signif-
icant difference in GSH-Red activity was observed be-
tween these two strains in different age groups (data not
shown).
DISCUSSION
Studies on MG and AGEs have been mainly focused
on their roles in diabetes mellitus and its complications. A
state of hyperglycemia as a precedent for MG and AGE
formation stimulates such studies. However, an associa-
tion of MG and AGEs with disease conditions with an ap-
parently normoglycemic state has not been investigated
intensively. Our study shows a strong association of MG
and its AGE products, CML and CEL, with hyperten-
sion in SHR. The blood pressure of SHR was not dif-
ferent from that of WKY rats at 5 weeks of age. From
8 weeks onwards, it was significantly elevated compared
to age-matched WKY rats. Importantly, this increase was
associated with a progressive increase in plasma MG lev-
els, which was significantly higher in SHR than in WKY
rats. MG levels in SHR kidney were also significantly
higher than in WKY rats from 13 weeks onward. More-
over, the levels of MG-induced AGEs, CML and CEL, in
the kidney were higher in SHR than in WKY rats from
8 weeks onward, in parallel with increased plasma MG
levels and blood pressure in SHR. On the other hand, no
hyperglycemia developed in SHR at different ages. It has
been shown that the glucose levels and insulin sensitivity
in SHR and WKY rats are comparable [18]. Our study
suggests that in addition to diabetes/hyperglycemic or hy-
perlipidemic conditions [19], MG is associated with the
development of high blood pressure in SHR, and indeed,
MG may be a causative factor for the development of hy-
pertension or its complications in this nondiabetic model.
This hypothesis is supported by the evidence, including
coincidental increase in plasma MG level with blood pres-
sure development, observed in our current study and the
induction of hypertension in WKY rats by chronic MG
feeding reported previously [11]. However, further stud-
ies are needed to clarify the causative role of MG in
hypertension. In comparison with glucose-induced gly-
cation that undergoes a reversible Maillard reaction with
N-terminal amino groups or lysyl chains to form fruc-
tosamine, an early glycation adduct, MG induces glyca-
tion through an oxidation process. This reaction is also
called glycoxidation, and it generates irreversible end gly-
cation adducts [6] including CEL and CML. With their
stable chemical property, CEL and CML have been inter-
preted as a measure of the status of oxidative stress and
of cumulative oxidative damage to proteins induced by
MG in aging and diabetes [4, 20]. In our study, antibodies
against CEL and CML were used. The antibody against
MG-induced CML is less selective since this antibody can
also react with glyoxal (another dicarbonyl compound)-
induced AGEs [20]. In contrast, anti-CEL antibody is
specifically against MG-induced CEL, and has been sug-
gested to be a good indicator for MG-induced AGE or
glycoxidation product [21].
The kidney plays a major role in blood pressure home-
ostasis [22], and possibly the pathogenesis of hyperten-
sion in SHR [23] and other models of hypertension, such
as DOCA-salt–sensitive hypertension [24]. The afferent
and efferent arterioles and the glomerular capillaries,
along with the renal proximal tubules and the thick as-
cending limb of the loop of Henle, regulate salt and wa-
ter absorption as part of the homeostatic mechanism. A
number of enzymes, including the cytochrome P450 and
various ion pumps, are involved. An alteration in the
function of one or more of these enzymes/proteins can
readily disturb the homeostatic mechanisms operating
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within the kidney, and lead to increased blood pres-
sure. AGE-induced renal injury was demonstrated in
vivo when diabetic mice were randomized to receive ei-
ther a regular diet or diet that had less AGE content.
Mice on the regular diet developed changes typical of
diabetic nephropathy, while mice on the low AGE diet
did not, even in the face of persistent hyperglycemia
[25]. Immunohistochemical studies of kidney from nor-
mal and diabetic rats have suggested that glomerular
basement membrane (BM), mesangium, podocytes, and
renal tubular cells accumulate high levels of AGEs. Ul-
trastructural studies have indicated that AGE peptides
may be reabsorbed by the renal proximal tubular cells
[26, 27]. AGE deposition can lead to glomerulosclero-
sis and widespread dysfunction, independent of diabetes.
This is evidenced by the development in nondiabetic
animals infused with AGE-albumin of glomerular pathol-
ogy resembling diabetic nephropathy, including glomeru-
lar hypertrophy, BM thickening, mesangial extracellular
matrix (ECM) expansion, and albuminuria [28]. Our im-
munohistochemical studies revealed a strong staining for
CML and CEL in the renal tubules and the glomerular
vessels of SHR compared to WKY rats from 8 weeks
onward. This suggests that an increased renal MG level
and MG-glycated proteins in kidney may induce local mi-
crovascular and tubular damage, consequently impairing
renal function. A chronically increased MG and related
AGE formation may lead to the development of high
blood pressure in SHR.
MG levels in plasma or tissues, including kidney, are
dependent on the balance between its anabolism and
catabolism. When the formation of MG exceeds its degra-
dation, accumulation of MG occurs even with normal
glucose levels. As mentioned earlier, the main source
of MG in mammals is glycolysis. The estimated rate
of MG formation in normal tissues is approximately
125 lmol/day, largely resulting from the fragmentation
of triosephosphates [1]. Approximately 0.1% to 0.4%
of glucose is metabolized to D-lactate in human red
blood cells and promyelocytic leukemia cells, which rep-
resents the maximum flux of MG formation [29]. Other
sources of MG are aminoacetone or acetone catalyzed by
semicarbadize-sensitive amine oxidase (SSAO) or ace-
tol mono-oxygenase (AMO) [2, 3], with former enzyme
found in high amounts within VSMC and in human
plasma [30, 31]. Increased activities of plasma SSAO and
AMO have been suggested to be responsible for the in-
creased circulating MG and endothelial dysfunction in
diabetes patients [30]. Moreover, SSAO enzyme levels
have been shown to be significantly elevated in nondia-
betic patients with congestive heart failure [32] and obe-
sity [33] compared to controls. In our study, MG levels
in plasma and kidney were significantly and age depen-
dently increased in SHR at different ages in compari-
son with the age-matched WKY rats (Fig. 1). A lower
MG level in kidney, but not in plasma, was also observed
from both SHR and WKY rats at the age of 20 weeks in
comparison with their relative younger age groups tested.
The exact mechanism for this age-dependent difference
is unclear yet. One possible explanation for this might be
a reduced MG formation in kidney in the aged rats. MG
formation in plasma is more complicated, linked to dif-
ferent circulating enzymes such as SSAO and MAO. An
age-dependent change in SSAO and MAO might be re-
sponsible for the alteration in circulating MG at different
ages in diabetes [30], as well as in hypertension. These
speculations need to be validated in the future.
Normal catabolism of MG is largely dependent on the
availability of cellular GSH, and the related enzyme ac-
tivities, including GSH-Px and GSH-Red. In our study,
the elevated levels of MG in plasma or kidney and MG-
induced CEL and CML in kidney of SHR were observed
as early as the age of 8 weeks. These changes preceded the
decreased GSH level and suppressed activity of GSH-Px
in kidney of SHR, which appeared at the age of 20 weeks.
At the same time, the GSH-Red activity also increased,
albeit not significantly. This increase may be a compen-
satory response to increased GSSG levels. The delayed
decrease of GSH in SHR indicates that the primary
reason for the early onset of MG increase could be the
abnormally increased MG production, rather than a dys-
functional MG degradation. Blood pressure of young
SHR begins to increase as MG level and its associated
oxidative stress level is progressively increased and the
antioxidant GSH system fails to compensate. Eventually,
GSH level will drop, and hypertension in aged SHR en-
ters a sustained stage.
CONCLUSION
MG levels in the plasma and kidney of SHR, but not
WKY rats, increased in an age-dependent manner asso-
ciated with the development of hypertension. Increased
MG and AGE formation in kidney may cause local dam-
age, contributing to both development and complications
of hypertension.
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